Abstract
Forty-eight patients with advanced breast carcinoma who had not received prior chemotherapy (minimum follow up 21 months) were randomised to receive either adriamycin 70 mg m-2 i.v. 3-weekly for 8 cycles (Regimen A) or adriamycin 35 mg m-2 i.v. 3-weekly for 16 courses (Regimen B). Objective responses were seen in 14/24 (58%) patients with regimen A (4 complete) and 6/24 (25%) with regimen B (1 complete) (P less than 0.02). The median duration of response was 14 months with regimen A and 6.5 months with regimen B. The median duration of survival was 20 months and 8 months respectively (P less than 0.01). The toxicity was similar with each regimen. There was no evidence of deterioration in left ventricular ejection fraction nor congestive heart failure in any patient. It is concluded that when given at 3-weekly intervals adriamycin is a more effective treatment for advanced breast cancer at higher rather than lower dosage.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carmo-Pereira, J., Costa, F., Henriques, E. et al. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 56, 471–473 (1987). https://doi.org/10.1038/bjc.1987.226
Issue Date:
DOI: https://doi.org/10.1038/bjc.1987.226
This article is cited by
-
Sublethal doxorubicin promotes migration and invasion of breast cancer cells: role of Src Family non-receptor tyrosine kinases
Breast Cancer Research (2021)
-
“First do no harm” and the importance of prediction in oncology
EPMA Journal (2010)
-
High dose epirubicin and cyclophosphamide in breast cancer stage IIIB
Clinical and Translational Oncology (2004)
-
Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: A new avenue to be explored
Current Oncology Reports (2003)
-
Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer
British Journal of Cancer (2002)